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Abstract The p22phox subunit is an essential protein in the
activation of NAD(P)H oxidase. Here we report the prelimi-
nary characterisation of the human p22phox gene promoter. The
p22phox promoter contains TATA and CCAC boxes and Sp1,
Q-interferon and nuclear factor UB sites. We screened for muta-
tions in the p22phox promoter and identi¢ed a new polymor-
phism, localised at position 3930 from the ATG codon, which
was associated with hypertension. Mutagenesis experiments
showed that the G allele had higher promoter activity than
the A allele. These results suggest that the 3930A=G polymor-
phism in the p22phox promoter may be a novel genetic marker
associated with hypertension.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
NAD(P)H oxidase is the major inducible source of super-
oxide anion (cO32 ) in phagocytes. In these cells, this enzyme
has a bactericidal function and generates cO32 upon stimula-
tion by pathogens [1]. This oxidase is a membrane-bound
enzyme that catalyses a single electron reduction of molecular
oxygen to form cO32 . It consists of a membrane-associated
cytochrome b558, two cytosolic components p47phox and
p67phox, and the small GTPase protein rac2 [2,3]. Cytochrome
b558, which is the ¢nal electron transporter from NAD(P)H to
molecular oxygen, consists of a large and a small subunit,
gp91phox and p22phox respectively [4].
The NAD(P)H oxidase system is also considered to be the
most important source of cO32 in vascular cells such as smooth
muscle cells (VSMCs) and endothelial cells [5^7]. Despite the
similarities between vascular and phagocytic NAD(P)H oxi-
dases, it has been suggested that vascular oxidase represents a
novel family of enzymes [8].
Oxidative stress induced by cO32 has been implicated in the
development of hypertension [9,10]. A major component of
NAD(P)H oxidase is the p22phox protein, a critical subunit
that plays an essential role in NAD(P)H oxidase-dependent
cO32 generation in vascular cells [11]. Enhanced vascular
NAD(P)H oxidase-driven cO32 production is associated with
upregulation of p22phox mRNA in several models of hyper-
tension, including the spontaneously hypertensive rat (SHR)
[12,13].
The gene encoding human p22phox (CYBA) is located on
chromosome 16q24 and has several allelic variants [14^17].
Recently we reported the existence of ¢ve functional polymor-
phisms in the promoter of the p22phox gene in SHR, associ-
ated with higher transcriptional activity [18]. Thus, the ¢rst
goal of this study was to perform the structural and functional
characterisation of the human p22phox gene, with the ¢nal
purpose of screening for new polymorphisms in its promoter
region.
2. Materials and methods
2.1. Subjects
The study population consisted of Caucasian subjects who were
referred to our institution for routine medical examination. The case
group of hypertensives consisted of 88 subjects with elevated systolic
blood pressure (SBPs 139 mm Hg) and/or elevated diastolic blood
pressure (DBPs 89 mm Hg). As a control group, 68 normotensive
subjects were also studied. Subjects agreed to participate in the study,
which was carried out in accordance with the Declaration of Helsinki,
and the protocol was approved by the Ethical Committee of the
University Clinic of Navarra.
2.2. Isolation of the p22phox gene 5P extreme
A human gene library constructed in vector P1 was screened by
conventional methods, and a positive clone was obtained. A fragment
of approximately 5 kb, obtained by digestion with SacI, was cloned in
plasmid pUC19, thus obtaining clone p5S. Sequencing of clone p5S
was performed using primers of vector pUC19 and internal primers
from the cloned fragment. Sequencing reactions were carried out in
both strands using the Autoread sequencing kit (Amersham).
2.3. Primer extension
Primer extension was carried out using a dye-labelled antisense
oligonucleotide (5P-ACATGGCCCACTCGATCT-3P) located at posi-
tions +8 to +25 relative to the ATG codon. The oligonucleotide was
hybridised with 1 Wg human kidney poly(A)þ RNA (Clontech) and
extended using Superscript II reverse transcriptase (Gibco BRL). The
products of this reaction were analysed by electrophoresis on a 6%
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polyacrylamide denaturing gel on the ALF1 DNA Analysis System
(Amersham) and the sizes of the products were determined by com-
parison with a DNA sequence obtained with the oligonucleotide used.
2.4. Plasmid construction
Digestion of clone p5S with SacI and Sau3AI released a fragment
of V1200 bp containing the whole promoter and the codon ATG of
the p22phox gene. This fragment was then subcloned in 5P position in
relation to the luciferase gene, in the SacI/BglII-digested pGL3basic
plasmid. We thus obtained the construct c1. Deleted constructs were
obtained by double digestion of c1, using SacI in the plus 5P end of
the promoter and di¡erent endonucleases (BalI, SmaI and ApaI) in
the plus 3P end of the promoter. The restriction ends were ¢lled using
the DNA polymerase I Klenow fragment, and the blunt edges were
ligated for subsequent transformation. As a result of this approach,
constructs c2, c3 and c4 were obtained. For the in vitro mutagenesis
experiments we employed construct c1, which contains the G allele at
the 3930 polymorphic site, as a template. The mutated construct,
in which the G allele at the 3930 polymorphic site in the p22phox
promoter was replaced by the A allele, was obtained using the
QuikChange Site-Directed Mutagenesis kit (Stratagene) with the
primers 5P-GGGGAATAAACCAGCATTACTGCCTCCGGCCTC-
CG-3P and 5P-CGGAGGCCGGAGGCAGTAATGCTGGTTTATT-
CCCC-3P. Correct orientation and sequence of the p22phox promoter
in all constructs were con¢rmed by restriction enzyme analysis, poly-
merase chain reaction (PCR), and DNA sequencing.
2.5. Cell culture, transfection experiments and luciferase activity
Primary VSMCs were obtained from thoracic aorta of 30-week-old
SHR as previously reported [19]. The rat aortic smooth muscle cell
line A7r5 was cultured in Dulbecco’s modi¢ed Eagle’s medium with
10% foetal calf serum supplemented with sodium pyruvate. A7r5 or
VSMCs were transfected as previously reported [19] and the assays for
luciferase activity were performed using Dual-Luciferase Reporter
Assay System (Promega). The ratio of ¢re£y luciferase level to Renilla
luciferase level was used as a measurement of p22phox promoter ac-
tivity.
2.6. Identi¢cation of polymorphisms in the p22phox promoter
To screen for mutations in the p22phox promoter, genomic DNA
was extracted from blood and a 1167-bp fragment containing the
whole promoter was ampli¢ed by PCR using the primers 5P-CAGG-
GAAGGGTCACTGTG-3P and 5P-ACATGGCCCACTCGATCT-3P.
The PCR products were sequenced directly using a Thermo Sequenase
kit (Amersham) after column puri¢cation.
2.7. Genotyping
Since the A-to-G mutation of the 3930A=G polymorphism introdu-
ces a BbvI digestion site, restriction fragment length polymorphism
(RFLP) was used to analyse this polymorphism in all subjects. A 650-
bp fragment containing the 3930 site was ampli¢ed employing the
oligonucleotides F1 (5P-GGAAACCACCAAGTGCCTCGGATGG-
3P) and R1 (5P-TCTGCACCCTGCTACCAAGGAC-3P). Digestion
of the PCR product by BbvI yields 504-, 85-, 57- and 15-bp fragments
in the G allele, whereas BbvI makes 589-, 57- and 15-bp fragments in
the A allele. Genotypes were scored according to the patterns of DNA
bands, and the results were con¢rmed by duplicate analysis. To be
sure of the accuracy of the method, a subset of 650-bp fragments were
sequenced.
2.8. Statistical analysis
Data are expressed as meanUS.E.M. M2 analysis was used to test
for deviation of genotype distribution from Hardy^Weinberg equilib-
rium and to determine whether there were any signi¢cant di¡erences
in allele or genotype frequencies between cases and controls. Statisti-
cal signi¢cance in the luciferase activity experiments among constructs
and in the clinical data among genotypes was assessed by ANOVA
followed by Sche¡e¤ post-hoc test. Di¡erences in the luciferase activity
Fig. 1. Nucleotide sequence of the human p22phox gene promoter. Consensus sites for transcriptional factors are underlined. The nucleotide
number was counted from the ATG codon. Arrows indicate the 5P end of the p22phox promoter constructs shown in Fig. 2. The asterisk indi-
cates the polymorphic site and the two alleles. The arrowhead (S) indicates the transcriptional start site. The nucleotide sequence has been
submitted to the GenBank data bank with accession number AY128666.
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experiments between allelic variants were assessed by Student’s t-test.
A P value 6 0.05 was considered statistically signi¢cant.
3. Results
3.1. Structure of the p22phox gene 5P extreme
Sequence analysis of clone p5S corroborated the presence of
the ¢rst four exons and three introns, which are £anked by
typical splice donor and acceptor dinucleotides, with an iden-
tical sequence to the previously reported human p22phox gene
exon^intron organisation [14]. In addition, we identi¢ed 1173
bp located upstream of the ATG codon corresponding to the
promoter region. Computer analysis of this sequence showed
the presence of a TATA box and a CCAC box. Other poten-
tial binding sites for GAGA elements, Q-interferon and nu-
clear factor UB (NF-UB) that might transcriptionally regulate
p22phox gene expression were also identi¢ed (Fig. 1). It is
interesting to note the presence of multiple binding sites for
the SP1 transcription factor close to the ATG codon. A prim-
er extension experiment pointed to a C located 231 nucleoti-
des upstream of the codon ATG as the predominant site for
transcription initiation (Fig. 1).
3.2. Promoter activity of the p22phox gene
In order to establish if the potential promoter region was
functional, a fragment of 1185 bp containing the whole pro-
moter was subcloned in a plasmid carrying the luciferase gene
(c1 clone) (Fig. 2A) and transfected in A7r5 cells. Fig. 2B
shows a substantial promoter activity of construct c1 in
A7r5 cells. To characterise more precisely the regions required
to control promoter activity, we cloned a series of DNA frag-
ments of the p22phox promoter obtained by progressive dele-
Fig. 2. A: Deletion mutants of the human p22phox promoter^lucifer-
ase constructs. B: Analysis of the human p22phox gene promoter.
A7r5 cells were transfected with the indicated plasmids, and lucifer-
ase activity was measured. Values represent meansUS.E.M. of ¢ve
separate determinations, performed in duplicate. *P6 0.05 com-
pared with c1, c2 and c3.
Table 1
General clinical characteristics of normotensives and hypertensives
Normotensives Hypertensives P
Gender, male/female 56/12 68/20 NS
Age, years 48U 1 56U 1 6 0.05
Body mass index, kg/m2 25.9U 0.4 28.7U 04 6 0.05
Smokers, n 27 25 NS
Diabetes, n 4 3 NS
Systolic blood pressure, mm Hg 115U 1 159U 2 6 0.05
Diastolic blood pressure, mm Hg 76U 1 93U 1 6 0.05
Mean arterial pressure, mm Hg 89U 1 115U 1 6 0.05
Pulse pressure, mm Hg 39U 1 65U 2 6 0.05
Glucose, mg/dl 100U 2 101U 1 NS
Total cholesterol, mg/dl 236U 5 243U 4 NS
HDL cholesterol, mg/dl 54U 2 50U 2 NS
LDL cholesterol, mg/dl 159U 5 167U 5 NS
Triglycerides, mg/dl 108U 8 139U 8 6 0.05
NS: not signi¢cant.
Fig. 3. A: Polymorphism 3930A=G was genotyped by digesting with
BbvI a 650-bp fragment of the p22phox promoter ampli¢ed by PCR
with primers F1 and R1. Vertical arrows indicate restriction sites for
the BbvI enzyme. B: Representative agarose gel electrophoresis of
BbvI RFLP of the p22phox gene.
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tion of the c1 clone (Fig. 2A). The resulting plasmids were
transfected in A7r5 cells. As shown in Fig. 2B, constructs c2
and c3 generated signals similar to those obtained with con-
struct c1. However, the promoter activity of construct c4
showed a signi¢cant decrease (P6 0.05).
3.3. Identi¢cation of a new polymorphism in the human p22phox
promoter
To search for polymorphisms in the 5P £anking region of
the human p22phox gene, a 1167-bp fragment corresponding to
the p22phox promoter was ampli¢ed from genomic DNA from
20 patients with essential hypertension and sequenced as de-
scribed above. Computer analysis of the p22phox promoter
sequences revealed the existence of A-to-G substitution at
3930 from the ATG codon (Fig. 1).
3.4. Association of the 3930A=G polymorphism of the
p22phox gene with essential hypertension
The clinical characteristics of subjects classi¢ed according
to blood pressure values are shown in Table 1. A total of 88
hypertensives and 68 normotensives were genotyped for the
3930A=G polymorphism by RFLP (Fig. 3). Distributions of
genotypes and alleles from both groups are presented in Table
2. Genotype frequencies were consistent with the Hardy^
Weinberg equilibrium law. Frequencies of genotypes for the
3930A=G polymorphism in hypertensive patients di¡ered sig-
ni¢cantly from those in normotensive subjects (M2 = 6.4,
P6 0.02). No signi¢cant di¡erences were found in the clinical
characteristics of hypertensives classi¢ed according to
3930A=G polymorphism genotypes (Table 3).
3.5. Functional e¡ect of the 3930A=G polymorphism of the
p22phox gene
To investigate whether the G-to-A substitution had an ef-
fect on gene expression, transfection experiments on VSMCs
obtained from SHR rats with each allelic promoter^reporter
gene construct were carried out. The G allele exhibited higher
luciferase activity than the A allele in SHR cells. As shown in
Fig. 4, reporter gene expression driven by the G allelic p22phox
promoter was 30% higher (P6 0.05) than reporter gene ex-
pression directed by the A allelic promoter.
4. Discussion
In the present study we have characterised the promoter
region of the human p22phox gene for the ¢rst time. The hu-
man p22phox promoter possesses a typical TATA and a CCAC
box and several potential consensus sequences for transcrip-
tional factors, such as GAGA elements, Q-interferon and NF-
UB. Furthermore, we have identi¢ed several SP1 binding sites
in close proximity to the ATG codon that can also play a
signi¢cant role in p22phox promoter activity. The construct
c1, which contained 1173 bp upstream and 12 bp downstream
Table 2
Genotype and allele frequencies for p22phox 3930A=G polymorphism
in normotensives and hypertensives
Normotensives Hypertensives P
GG, n (%) 23 (33.8) 36 (40.9) 6 0.02
GA, n (%) 29 (42.6) 41 (46.6)
AA, n (%) 16 (23.5) 11 (12.5)
G allele frequency 0.55 0.64
A allele frequency 0.45 0.36
Table 3
p22phox 3930A=G genotypes and clinical characteristics in hypertensives
AA AG GG Signi¢cance
Gender, male/female 10/1 29/12 29/7 NS
Age, years 55U3 55U 1 56U 1 NS
Body mass index, kg/m2 27.8U 1.1 28.1U 0.5 29.8U 0.7 NS
Diabetes, n 1 2 0 NS
Systolic blood pressure, mm Hg 153U 6 162U 4 156U 3 NS
Diastolic blood pressure, mm Hg 86U2 94U 2 94U 2 NS
Mean arterial pressure, mm Hg 108U 2 117U 2 115U 2 NS
Pulse pressure, mm Hg 66U7 68U 4 62U 3 NS
Glucose, mg/dl 103U 4 102U 2 99U 2 NS
Total cholesterol, mg/dl 237U 9 241U 7 246U 7 NS
HDL cholesterol, mg/dl 48U4 51U 3 49U 2 NS
LDL cholesterol, mg/dl 160U 14 160U 6 177U 9 NS
Triglycerides, mg/dl 135U 18 154U 13 124U 12 NS
NS: not signi¢cant.
Fig. 4. A: Schematic presentation of reporter gene constructs con-
taining the p22phox gene promoter, with the only di¡erence between
the two constructs being either a G or an A base at the 3930 site.
B: Luciferase levels in VSMCs from SHR transfected with reporter
gene constructs containing A (c1-A) or G (c1-G) allelic p22phox gene
promoter. Data shown are meansUS.E.M. values from six separate
experiments, performed in duplicate. *P6 0.05 compared with c1-A.
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of the ATG codon, was used for luciferase reporter gene as-
says. In this regard, a substantial promoter activity of con-
struct c1 proved the functionality of this promoter. However,
we observed a signi¢cant decrease in the promoter activity of
construct c4. Deletion analysis of the promoter region re-
vealed that TATA and CCAC boxes and several putative
binding sites such as Elk1, GAGA and NF-UB, situated be-
tween positions 3201 and 3429, may be important for the
basic promoter activity.
The main ¢nding of the current study is the identi¢cation of
a new polymorphism within the p22phox gene promoter, lo-
cated at position 3930 from the ATG codon. Genotyping
studies of this polymorphism in cases and controls showed a
signi¢cant increase in G allele frequency in hypertensives. Our
group has recently reported the presence of functional poly-
morphisms in the p22phox promoter that resulted in a higher
transcriptional activity of the p22phox gene in SHR [18]. In the
same study we showed that VSMCs obtained from the aorta
of SHR exhibit a characteristic hypertensive phenotype. Thus,
these cells represent a good in vitro model for the study of the
e¡ects of hypertensive stimuli on the allelic variants of the
3930A=G polymorphism and hence on the promoter activity.
In this regard, our ¢ndings showing a higher reporter gene
expression driven by the G allelic p22phox promoter than that
of the A allelic promoter in SHR VSMCs would suggest that
this polymorphism is functionally relevant. In a multifactorial
chronic disease such as hypertension, a p22phox transcriptional
activity 30% higher for the G allele than for the A allele could
be expected to play a signi¢cant role in this trait. Thus, these
observations suggest that the 3930A=G polymorphism may be
involved in the control of the expression of the p22phox gene
under hypertensive conditions, although new studies are nec-
essary to address the in£uence of genotypes on p22phox
mRNA expression.
Recent ¢ndings have claimed the potential relevance of
p22phox gene overexpression in hypertension [20]. An increased
p22phox mRNA expression leading to a greater NAD(P)H
oxidase-driven cO32 production has been reported in SHR
with diminished nitric oxide availability and endothelial dys-
function [12]. On the other hand, we have shown that p22phox
polymorphisms are able to regulate p22phox expression and
consequently NAD(P)H oxidase activity in SHR [18]. It is,
thus, tempting to speculate that the polymorphism of the
p22phox gene reported here may upregulate the expression
and activity of NAD(P)H oxidase in hypertension. Although
further functional studies are required to test this hypothesis,
its signi¢cance is underlined by clinical data, indicating the
occurrence of increased cO32 production in hypertensives
[21,22]. Nevertheless, we cannot discard the possibility that
3930A=G polymorphism could be in linkage disequilibrium
with another functional polymorphism.
In summary, we have characterised the genomic structure of
the human p22phox gene promoter. In addition, we have iden-
ti¢ed the 3930A=G polymorphism in the p22phox promoter
that appears to be a novel genetic marker associated with
hypertension. Since this is a pilot study, it is necessary to
con¢rm these preliminary results in further studies. Neverthe-
less, our ¢ndings show that expression of the p22phox mRNA
in hypertension depends on the presence on the G or A allele
for this polymorphic site.
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